Novartis comes for a Biogen MS drug with new biosimilar

On Thursday, the U.S. Food and Drug Administration approved a new biosimilar designed to mimic Tysabri, one of Biogen’s (Nasdaq: BIIB) MS products. Biosimilars, like generics, are typically more affordable versions of brand-name drugs.